Trial Profile
A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase I/2a Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Biotech (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Kangstem Biotech
- 07 Oct 2022 Status changed from recruiting to completed.
- 09 Jul 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Feb 2021.
- 09 Jul 2020 Status changed from active, no longer recruiting to recruiting.